Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 12/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21464054 | 0.91 | PRKCQ (0.48) | PRKCQPDE4BPRKCAMAP3K11DAO | |
| SCHEMBL30615537 | 0.91 | PRKCQ (0.48) | PRKCQPDE4BPRKCAMAP3K11DAO | |
| SCHEMBL21463602 | 0.81 | PDE4B (0.48) | PDE4BMAP3K11DAOGRM4ALDH1A1 | |
| SCHEMBL30615379 | 0.81 | PDE4B (0.48) | PDE4BMAP3K11DAOGRM4ALDH1A1 | |
| SCHEMBL30615608 | 0.80 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL21463914 | 0.80 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL30615535 | 0.79 | PRKCQ (0.44) | PRKCQPRKCADAOALDH1A1GRIN1 | |
| SCHEMBL30615357 | 0.77 | PRKCQ (0.51) | PRKCQPDE4BPRKCADAOALDH1A1 | |
| SCHEMBL16348540 | 0.77 | DAO (0.53) | PRKCQPRKCADAOALDH1A1GRIN1 | |
| SCHEMBL24405999 | 0.76 | PDE4B (0.48) | PDE4BGRM4ALDH1A1RXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |